Stock research
CAPR Capricor Therapeutics, Inc.
Healthcare • Biotechnology
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare...…
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
5Y change
-4.12%
Range high
$35.34
Congress · 90d
0
Insiders · 90d
0
Public signal layer
Who is disclosing activity in CAPR?
Price
Showing 5Y history. Source: FMP historical price full.
- Prev Close
- $6.57
- Day High
- $4.21
- Day Low
- $2.96
- 52w High
- $40.37
- 52w Low
- $2.96
- Volume
- 28,762,271
- Avg Volume
- Beta
- 0.419
* TTM/most recent where available
Company
- Ticker
- CAPR
- Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- CEO
- Linda Marbán
- Employees
- 231
- Website
- www.capricor.com
Key Metrics
- Market Cap
- 243M
- P/E
- P/B
- P/S
- EV/EBITDA
- ROE
- Net Margin
- Div Yield
- FCF/Share
* TTM/most recent where available
DCF Valuation
Standard DCF
Levered DCF
Market Price
DCF vs Price (30D window)
Price uses last 30 days; DCF line holds latest value across the window.DCF line = solid green (latest value repeated across window), Price = dashed blue (daily closes).